Stock Screener App

Gratuito -

Installare

1.44

2.86% 0.04

after-market

Dopo l'orario di chiusura: 1.55 0.11 +7.64%

In 8 Bio Inc (INAB)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione

In 8 Bio Inc Borsa (INAB) Ultime notizie

Climb Bio, Inc. 8-K Filing Details: Company Information, Address, and Stock Exchange Listing (April 2026) - minichart.com.sg

Climb Bio (CLYM) consolidates CFO and principal accounting officer roles - Stock Titan

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.

Instil Bio (TIL) replaces Deloitte with RSM as independent auditor - Stock Titan

[144] Annovis Bio, Inc. SEC Filing - Stock Titan

Palisade Bio (NASDAQ: PALI) sells 1.54M shares to Iterative Health affiliate - Stock Titan

GOSS SEC FilingsGossamer Bio 10-K, 10-Q, 8-K Forms - Stock Titan

KALA SEC FilingsKala Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan

APTN SEC FilingsAdaptin Bio 10-K, 10-Q, 8-K Forms - Stock Titan

LeonaBio (NASDAQ: ATHA) expands Sermonix deal disclosure and ELAINE-3 trial spend - Stock Titan

ImmunityBio (NASDAQ: IBRX) adds $75M non-dilutive cash and converts $25M debt - Stock Titan

Passage Bio Inc Stock: Gene Therapy Innovator Faces Clinical and Funding Hurdles in Competitive Biot - AD HOC NEWS

Vor Bio (Nasdaq: VOR) secures $75M private placement to fund telitacicept - Stock Titan

[8-K] Instil Bio, Inc. Reports Material Event - Stock Titan

Tela Bio targets at least 8% revenue growth in 2026 while advancing commercial transformation - MSN

LeonaBio (NASDAQ: LONA) boosts cash to fund Phase 3 breast cancer drug - stocktitan.net

Upstream Bio (NASDAQ: UPB) establishes $150M at-the-market stock program - Stock Titan

bioAffinity Technologies (BIAF) shares March 2026 investor presentation materials - Stock Titan

Upstream Bio (NASDAQ: UPB) deepens 2025 loss while推进 Phase 3 verekitug strategy - Stock Titan

Tevogen Bio Holdings Inc. Files Form 8-K on NASDAQ: Company Details and Key Information for March 2026 - Minichart

Annovis Bio, Inc. Files Form 8-K with NYSE Listing and Corporate Information for March 23, 2026 - Minichart

Annovis Bio's Mark Guerin departs as CFO; Maria Maccecchini to serve as Acting CFO - TradingView

CFO departs Annovis Bio (ANVS) as CEO Maria Maccecchini takes acting finance role - Stock Titan

Tevogen Bio (TVGN) restores Nasdaq bid-price compliance after 1-for-50 reverse split - Stock Titan

bioAffinity Technologies (BIAF) plans CyPath Lung webinar showcasing real-world clinical use - Stock Titan

TELA Sees Growth with FY26 Revenue Projected to Rise at Least 8% - GuruFocus

TELA Bio (NASDAQ: TELA) lifts 2025 sales 16% but posts $38.8M loss - Stock Titan

Medical device maker secures up to $70M after 18% sales gain - Stock Titan

INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th. - The Manila Times

INmune Bio will discuss 2025 results and corporate update March 30 - stocktitan.net

PALI SEC FilingsPalisade Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Cabaletta Bio (NASDAQ: CABA) details 2025 results and advances rese-cel trials - Stock Titan

ANVS SEC FilingsAnnovis Bio Inc 10-K, 10-Q, 8-K Forms - stocktitan.net

UPB SEC FilingsUpStream Bio Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Palisade Bio Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView

TELA Bio Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

TELA Bio (TELA) hit with Nasdaq $1 bid-price deficiency, faces delisting risk - Stock Titan

NUVB SEC FilingsNuvation Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan

[8-K] BIO-PATH HOLDINGS, INC. Reports Material Event | BPTH SEC FilingForm 8-K - Stock Titan

LeonaBio (ATHA) wins approval for 2026 equity plan and major share increase - Stock Titan

[EFFECT] Gossamer Bio, Inc. SEC Filing - Stock Titan

Passage BIO (PASG) CEO receives 58,000-share stock option grant - Stock Titan

[144] KALA BIO, Inc. SEC Filing - Stock Titan

Gossamer Bio (NASDAQ: GOSS) 2025 loss widens as seralutinib Phase 3 misses goal - Stock Titan

Phase 3 trial push deepens 2025 loss at Annovis Bio (NYSE: ANVS) - Stock Titan

Kyntra Bio (Nasdaq: KYNB) unveils 2025 results, FG-3246 and roxadustat plans - Stock Titan

INmune Bio Receives $8 Consensus Price Target from Analysts - National Today

KRRO SEC FilingsKorro Bio, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

[8-K] Bio Green Med Solution, Inc. Reports Material Event | BGMS SEC FilingForm 8-K - Stock Titan

CyPath Lung growth accelerates while bioAffinity (NASDAQ: BIAF) posts larger 2025 loss - Stock Titan

Morgan Stanley Smith Barney files Form 144 to sell restricted KALA shares (KALA) - Stock Titan

Adicet Bio (NASDAQ: ACET) outlines 2025 loss and cash runway into 2027 - Stock Titan

Korro Bio (NASDAQ: KRRO) expands RNA-editing pipeline as 2025 net loss deepens - Stock Titan

Form 144: Restricted stock sale notice — Kala Pharmaceuticals (NASDAQ: KALA) - Stock Titan

ACET SEC FilingsAdicet Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

BioXcel Therapeutics (NASDAQ: BTAI) completes $7.8M equity and warrant financing - Stock Titan

$180B AI healthcare play: KALA BIO pivots with first agent - Stock Titan

Passage Bio (PASG) pays $4.8M to end long-term Hopewell lab lease - Stock Titan

Korro Bio Raises $85 Million in Private Placement, Adds Investor Registration Rights - TradingView

Korro Bio (KRRO) secures $85M PIPE to extend cash runway into 2028 - Stock Titan

Boundless Bio (Nasdaq: BOLD) trims 2025 loss, funds KOMODO-1 into 2028 - Stock Titan

RVMD

$99.12

0.49%

ROIV

$28.33

1.76%

RPRX

$48.57

0.16%

BNTX

$91.18

1.97%

ONC

$310.79

0.76%

INSM

$162.43

1.47%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters